Custom Bonding and Chromatography Resins for Small and Large Molecule Purification

Product Description
W. R. Grace & Co

-
US
-
2015On CPHI since
-
1000 - 4999Employees
Company types
Categories
W. R. Grace & Co

-
US
-
2015On CPHI since
-
1000 - 4999Employees
Company types
More Products from W. R. Grace & Co (4)
-
Product Custom Fine Chemical Manufacturing
Our comprehensive portfolio of services, integrated manufacturing, and regulatory leadership differentiates us as a leading contract development and manufacturing partner. With a proven ability to deliver solutions to complex challenges, Grace’s FCMS supports the entire small molecule development cycle from t... -
Product Purification and Formulation of Oily APIs and Omega-3s
Grace resins and excipients improve purity and create better targeted and higher value formulations with enhanced bioavailability. Grace is solving purification and formulation issues in oily APIs and Omega-3s in high quality separation capabilities, customization, reliability and speed to market, and com... -
Product Purification and Formulation of Cannabinoids (CBD)
Grace has developed and introduced a patented silica based carrier, SYLOID® XDP silica, to directly convert liquid ingredients such as CBD into solid dosage forms. Extracting and purifying CBD from the hemp plant is a multi-step process which focuses on removal of several undesirable impurities. Grace has... -
Product Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds
Engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to effectively formulate a large class of poorly soluble but otherwise promising compounds, Grace’s SILSOL® silica-based drug delivery technology provides solutions for poorly soluble active...
W. R. Grace & Co resources (3)
-
News Grace Completes Acquisition of Fine Chemistry Business
June 01, 2021: W. R. Grace & Co. announced the completion of its acquisition of the Fine Chemistry Services business (“FCS”) of Albemarle Corporation (NYSE: ALB) for approximately $570 million, including $300 million paid in cash and $270 million funded through the issuance to Albemarle of non-participating preferred equity of a newly created Grace subsidiary.
-
Brochure Grace Pharmaceutical Solutions Brochure
Learn more about Grace's unmatched quality and reproducibility of our fine chemicals, chromatography resins, formulation excipients, and active ingredient delivery technologies. -
Video Natural Extracts: Unlocking the Potential of Cannabinoid Derived Drugs
Originally aired during the CPHI Festival of Pharma 2020, this webinar examines the current landscape for cannabinoid derived drugs, including looking at pipeline and approvals, development challenges and regulatory hurdles.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance